Today’s guest is Andrew Bolt, Partner at Deloitte. He joins Emerj CEO and Head of Research Daniel Faggella on today’s podcast to talk about challenges in R&D  for life sciences. While productivity has remained stagnant for the last 10-15 years, advances in AI-enhanced protein structure prediction are revolutionizing drug targeting and the very infrastructure of recruiting patients for clinical trials. Later, the two postulate on the ways AI can expedite regulatory compliance in pharmaceutical R&D in similar ways. Find out more about sponsored content and how to engage with the Emerj audience at emerj.com/ad1.